As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales of the Spikevax® and Comirnaty® COVID-19 vaccines.
Key suits were filed by third party mRNA and lipid pioneers that, while not having any mRNA-based products on the
In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact with unique receptors on disease-causing cells while avoiding interaction with healthy cells.
Over a century later, Antibody Drug Conjugates (ADCs) – which are a species of Ehrlich’s “magic bullet” concept – have been developed by
Although the Corporate Transparency Act (the “CTA”) is no longer halted by nationwide preliminary injunctions, U.S. companies and their beneficial owners are not required to report beneficial ownership information pursuant to the CTA.
FinCEN Issues Interim Final Rule
In the most recent CTA update from March 21, 2025, the Financial Crimes Enforcement Network (“FinCEN”) issued
For the past few months, the beneficial ownership reporting obligations under the Corporate Transparency Act (the “CTA”) have fluctuated between being required pursuant to the CTA and being halted by nationwide preliminary injunctions. However, as of February 18, 2025, all nationwide preliminary injunctions have been lifted and compliance with the CTA is again required. Thus,
Co-authored by Sheena Wang and Ellie Purnell of HGF limited, “CRISPR and Agriculture” was originally published by Food and Drink Technology on January 29, 2025. To access the article on the Food and Drink Technology website, please click here.
Modern gene-editing technology, such as CRISPR/Cas technology, represents a ground-breaking advancement that has transformed our
Only days after lifting the nationwide preliminary injunction, the Fifth Circuit Court of Appeals vacated their decision to stay the district court’s preliminary injunction enjoining enforcement of the Corporate Transparency Act. In the December 26, 2024 decision, Fifth Circuit stated:
The merits panel now has the appeal, which remains expedited, and a briefing schedule will
As an update to our posts on the ongoing attempts to block the Corporate Transparency Act, on December 23, 2024, the Fifth Circuit granted a temporary stay of the district court’s preliminary injunction for compliance with the Corporate Transparency Act in Texas Top Cop Shop, Inv. v. Garland.[1] The Fifth Circuit’s decision reinstated the January
As an update to our post on the Corporate Transparency Act, on December 3, 2024, a federal district court issued a nationwide preliminary injunction pertaining to the Corporate Transparency Act in Texas Top Cop Shop, Inc. v. Garland. In its ruling, the court stated that “reporting companies need not comply with the CTA’s January 1,
The United States Patent and Trademark Office (USPTO) announced today the finalized fee increases taking effect on January 19, 2025. While applicants can still expect significant increases in certain areas, some proposed fee increases were not implemented following pushback from public commentators. One notable example relates to terminal disclaimers. The USPTO had proposed a tiered
The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is no exception.
AI-driven platforms have become increasingly useful to biotech innovators in many areas including in discovering and developing drugs. For example, a 2022 article by McKinsey & Company estimated that nearly 270 companies have
